Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Surish Shanmugam MBChB, MSc, RCP(UK) (Medical Oncology)

Surish P. Shanmugam MBChB, MSc, RCP(UK) (Medical Oncology)

Master's student, Harvard Medical School, Boston, Massachusetts

Dr. Surish Shanmugam obtained his medical degree from the University of Glasgow, UK and subsequently obtained a Master’s degree in Drug Discovery & Protein Biotechnology from the University of Edinburgh, UK. He is a UK board certified medical oncologist with a keen interest in Oncology Drug Discovery and Translational Research and has also spent around 6 years working in industry as a pharmaceutical physician/oncologist, specifically on GU and GI oncology as well as leukemia. He has recently undertaken a Master's degree focused on cancer translational research at Harvard Medical School and joined Dr. Kent Mouw’s lab at the Dana Farber Cancer Institute to pursue wet lab/translational research in the urothelial cancer (UC) space, specifically in relation to Homologous Recombination Repair deficient and Nucleotide Excision Repair deficient UC respectively.

Dr. Surish also has a side interest in Health Economics and holds a Master’s degree in Health Economics & Pharmaco-economics. As much as he is deeply passionate about cancer research, he is equally passionate about finding practical and sustainable solutions that will greatly increase patient access to high quality cancer treatments.


No disclosures reported.